Cell Therapy Manufacturing Automation Market Report 2026

Cell Therapy Manufacturing Automation Market Overview

• Cell Therapy Manufacturing Automation market size has reached to $1.81 billion in 2025 • Expected to grow to $3.58 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Growing Demand For Gene Therapies Fueling The Growth Of The Market Due To The Need For Scalable, Standardized, And High-Quality Production Processes • Market Trend: Automation Software Integration Drives Workflow Standardization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the Cell Therapy Manufacturing Automation market include: • Hardware (Segmentation By Component ) → Expected gain of $0.82 Billion • Software (Segmentation By Component ) → Expected gain of $0.69 Billion • Services (Segmentation By Component ) → Expected gain of $0.30 Billion

What Is Covered Under Cell Therapy Manufacturing Automation Market?

Cell therapy manufacturing automation refers to the use of automated, robot- or software-driven systems for cell isolation, expansion, processing, and quality control to improve scalability, consistency, and sterility in cell therapy production. This market includes automated closed-system bioreactors, robotic cell-handling platforms, automated cryopreservation units, integrated quality-control and monitoring tools, and software solutions for workflow control, electronic batch records, and GMP compliance. The main components of cell therapy manufacturing automation solutions are hardware, software, and services. Hardware comprises automated processing equipment, bioreactors, and integrated systems that support scalable, consistent, and compliant cell therapy production workflows. These solutions are used across cell types including T-cells, stem cells, natural killer cells, and others, applied in upstream processing, downstream processing, fill-finish, quality control, and others, among end users such as pharmaceutical and biotechnology companies, research institutes, contract manufacturing organizations, and others.

What Is The Cell Therapy Manufacturing Automation Market Growth Forecast?

The cell therapy manufacturing market size is expected to see rapid growth in the next few years. It will grow to $3.58 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing personalized-therapy volumes, growing investment in automation platforms, rising need for contamination-free workflows, expansion of large-scale commercial manufacturing, and increasing regulatory-driven quality requirements. Major trends in the forecast period include technology advancements in closed systems, automation-driven process innovations, integrated workflow developments, real-time analytics research, and advanced robotics research and development.

What Is The Driver Of The Cell Therapy Manufacturing Automation Market?

The growing demand for gene therapies is expected to propel the growth of the cell therapy manufacturing automation market going forward. Gene therapy refers to a medical technique that involves modifying or replacing defective genes to treat or prevent diseases. The increasing demand for gene therapy is due to advancements in genetic sequencing and diagnostics, which enable precise identification of disease-causing genes for targeted treatment. Cell therapy manufacturing automation supports gene therapy by streamlining and standardizing complex production processes to ensure consistent quality and scalability. It enhances therapeutic development by reducing errors, improving efficiency, and enabling reliable large-scale manufacturing of gene-modified cells. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five approvals in 2022. Therefore, the growing demand for gene therapies is driving the growth of the cell therapy manufacturing automation industry.

How Will The Drivers Impact Growth In The Global Cell Therapy Manufacturing Automation Market?

• Increasing Commercialization Of Cell Therapies (High) – During the forecast period, the increasing commercialization of cell therapies will be a key growth driver for the cell therapy manufacturing automation market by 2030. Moving cell therapies from development into commercial use increases the number of batches that manufacturers must process reliably. Automated systems can coordinate cell handling and production steps while reducing repetitive manual activity. Consistent execution becomes more important as treatment demand expands across sites. Commercialization therefore creates opportunities for equipment and software that support repeatable production within defined manufacturing procedures. • Growing Need For Scalable And Standardized Manufacturing (High) – During the forecast period, the growing need for scalable and standardized manufacturing will be a major factor supporting expansion of the cell therapy manufacturing automation market by 2030. Manufacturers need to increase output without allowing process variability to undermine product quality. Automation can help standardize cell processing conditions, handling sequences, and equipment operation across batches. Integrated systems also make it easier to coordinate production steps as capacity grows. Demand for predictable scale-up encourages investment in tools that support consistent execution of validated manufacturing workflows. • Stringent Regulatory And Quality Compliance Requirements (Medium) – During the forecast period, the stringent regulatory and quality compliance requirements will be a key growth catalyst for the cell therapy manufacturing automation market by 2030. Cell therapy production requires documented process controls, traceability, and checks suited to sensitive biological products. Automated systems can capture operating information and apply defined procedures more consistently, helping manufacturers review batch performance. This supports quality management when combined with validation and oversight. Requirements for reliable records and controlled processing encourage adoption without making automation a substitute for regulatory responsibility.

How Will The Restraints Impact Growth In The Global Cell Therapy Manufacturing Automation Market?

• High Initial Capital Investment (High) – During the forecast period, high initial capital investment is a major restraint for the cell therapy manufacturing automation market, as implementing automated systems requires substantial upfront spending. Companies must invest in advanced robotics, software platforms, closed-system equipment, facility upgrades, and system validation, significantly increasing capital expenditure. Small and mid-sized biotechnology firms often face financial constraints that limit their ability to adopt these technologies. In addition, the long return on investment and ongoing maintenance costs further discourage early adoption. These financial barriers can slow the widespread deployment of automated manufacturing solutions, particularly in emerging markets and smaller production facilities. • Complex Integration And Regulatory Compliance (High) – During the forecast period, complex integration and regulatory compliance act as significant restraints on the cell therapy manufacturing automation market. Integrating automated systems with existing manufacturing infrastructure, laboratory equipment, and digital platforms can be technically challenging and time-consuming. Manufacturers must also ensure that automated processes comply with evolving regulatory standards, including Good Manufacturing Practice (GMP) requirements and validation protocols. Frequent regulatory updates often require additional testing, documentation, and system modifications, increasing implementation costs and project timelines. These challenges can delay automation adoption, particularly for organizations with limited technical expertise or resources. • Shortage Of Specialized Automation And Process Development Skills (Medium) – During the forecast period, a shortage of specialized automation and process development skills will restrain the cell therapy manufacturing automation market by limiting implementation and operational support capacity. Successful projects require expertise spanning cell biology, process engineering, software configuration, equipment qualification, and quality management. Organizations may find it difficult to recruit or train personnel who can translate variable biological processes into reliable automated workflows. Limited internal expertise can increase dependence on equipment vendors and external consultants. These constraints can prolong technology transfer, commissioning, and process optimization, particularly for smaller therapy developers.

Key Players In The Global Cell Therapy Manufacturing Automation Market

Major companies operating in the cell therapy manufacturing automation market are Thermo Fisher Scientific Inc., Merck KGaA, Fujifilm Holdings Corporation, Corning Incorporated, Lonza Group AG, Cytiva, WuXi AppTecCo. Ltd., Hitachi High Technologies Corp., CatalentInc., Sartorius AG, Beckman Coulter Life Sciences, Terumo BCT Inc., Miltenyi Biotec, Oxford Biomedica Plc, National Resilience LLC, Minaris Regenerative Medicine LLC, Tulip Interfaces Inc., Invetech Pty Ltd., BlueRock Therapeutics LLC, Cellares Inc., Ascential Medical & Life Sciences, Cell and Gene Therapy Catapult

Global Cell Therapy Manufacturing Automation Market Trends and Insights

Major companies operating in the cell therapy manufacturing automation market are focusing on developing advanced solutions, such as automated cell therapy system, to connect multi‑stage manufacturing workflows into unified, validated digital frameworks that reduce manual touchpoints and support regulatory compliance. An automated cell therapy system refers to an off‑the‑shelf validated automation solution that digitally connects cell therapy instruments (e.g., magnetic separation, centrifugation, electroporation, incubators) into a single interface, enabling traceability, repeatability, and cGMP compliance across production stages. For instance, in January 2024, Thermo Fisher Scientific Inc., a US‑based life sciences company, launched Gibco CTS Cellmation Software, a first-of-its-kind automation solution. It is a first-of-its-kind, off-the-shelf validated software solution that digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to automate manufacturing workflows. It includes a pre-validated automation system powered by Emerson’s DeltaV technology, enabling seamless integration and control of multiple instruments without costly custom projects, and it establishes traceable, repeatable workflows that help ensure compliance with cGMP and data security regulations, reducing manual touchpoints for ground therapy developers.

What Are Latest Mergers And Acquisitions In The Cell Therapy Manufacturing Automation Market?

In July 2024, Cellular Origins Ltd., a UK-based provider of automated cell and gene therapy manufacturing solutions, acquired the Autologous Cell Therapy Industrial Automation (ACTIA) Platform IP for an undisclosed amount. With this acquisition, Cellular Origins expanded its automated manufacturing technology portfolio by advancing the Constellation robotic platform to improve scalability, reduce production bottlenecks, and support industrialized cell therapy manufacturing workflows. ACTIA Platform IP is a US-based intellectual property platform focused specifically on industrial automation solutions for autologous cell therapy manufacturing

What Defines the Cell Therapy Manufacturing Automation Market?

The cell therapy manufacturing automation market consists of revenues earned by entities by providing services such as automated cell processing, workflow integration, process monitoring and control, digital manufacturing execution, and equipment validation and maintenance. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell therapy manufacturing automation market also includes sales of automated cell culture systems, robotic liquid handling platforms, closed system bioreactors, process control software, and integrated manufacturing hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cell Therapy Manufacturing Automation Market Report 2026?

The cell therapy manufacturing automation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy manufacturing automation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.